AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03688217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Philani Intervention Model+MOVIE (PIM+M)
Description: The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
Study NCT03688217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Philani Intervention Model (PIM)
Description: The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
Study NCT00407381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: Laser photocoagulation in either focal or grid pattern as determined by investigator.
Study NCT00788905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allient System
Description: The Allient System uses a different type of blood pump and a lower volume of dialysate.
Study NCT00588861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Answer® hip stem
Description: Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
Study NCT00588861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Answer® hip stem
Description: Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
Study NCT04314791 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound evaluation, with grayscale and color Doppler imaging
Description: In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
Study NCT01578824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Challenge Test
Description: Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
Study NCT03018249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT03018249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Undergo hysterectomy
Study NCT03018249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Undergo hysterectomy
Study NCT03018249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03018249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00874926 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Haemophilia A patients
Study NCT00514748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP
Description: flap survival, operation time, flap complications, donor site morbidity.
Study NCT03018249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone Acetate
Description: Given IM
Study NCT03018249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate
Description: Given IM
Study NCT00514748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interconnected DIEP
Description: flap survival, operation time, flap complications, donor site morbidity.
Study NCT01368562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
Study NCT04415242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positioning
Description: different positioning prior surgery
Study NCT04415242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positioning
Description: different positioning prior surgery
Study NCT02631382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet cupping
Description: In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected.
Study NCT04351074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: ligation of the intersphincteric fistula track
Study NCT04351074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fistulectomy
Description: excision of the fistulous track with its internal and external orifices
Study NCT01538251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
Study NCT03215563 — intervention group
Intervention type: RADIATION
Intervention: 18F PET-MRI
Description: 18F-fluoride Hybrid PET-MRI
Study NCT01538251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
Study NCT00862797 — intervention group
Intervention type: OTHER
Intervention: pressure measurement during swallowing
Description: measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
Study NCT03215563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Microembolic Signals detection
Study NCT02012244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl-based analgesia
Description: fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
Study NCT02012244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anesthetic wound infiltration-based anlagesia
Description: continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
Study NCT01051570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
Study NCT01051570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD 001
Description: 5 mg orally starting on Day 2 then continuous
Study NCT01051570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg orally twice a day starting on Day 1 then continuous
Study NCT01857921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin 20mg/day for 12 months after randomization
Description: Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization
Study NCT01857921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization
Description: Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization
Study NCT03047525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced Killer Cells
Description: Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
Study NCT00777179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Tablet, oral, daily
Study NCT00777179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01051570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Samples will be collected from archival tissue.
Study NCT01051570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Samples will be collected Cycle 1, day 1, 2 \& 8 and Cycle 2, Day 1 \& 2
Study NCT04622657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dubousset functional test
Description: Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
Study NCT02152566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High flow therapy device
Description: Nasal high flow therapy via nasal cannula.
Study NCT04348162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa flavanols and berries anthocyanins
Description: Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
Study NCT05279391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6-8 mg once daily
Study NCT03566329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
Study NCT03566329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
Study NCT05279391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
Study NCT03566329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion with the same rate of infusion as the study drugs
Study NCT03799510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm14
Description: Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
Study NCT03799510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE solution
Description: The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
Study NCT03692416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Study NCT03692416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Steroids for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Study NCT03692416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Study NCT01588275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Proper CPAP-pressure will be set for each patient separately.
Study NCT01636843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Study NCT03787914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Outreach Approach
Description: TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
Study NCT03787914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile Outreach Approach
Description: TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
Study NCT04273074 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: sonographic assessment
Description: preoperative sonographic assessment to airway
Study NCT04042194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF
Description: A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
Study NCT04042194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of Implants and Thickening Peri-Implant Mucosa with CTG
Description: The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
Study NCT02704598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
Study NCT02704598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
Study NCT04725279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Treatment: Physiotherapy, Electrotherapy or Exercises at home
Description: The 67 patients attended the rehabilitation consultation where, after taking the anamnesis, they began to perform balance tests with a stabilometric platform and those patients with associated neck pain, with cervical motion sensors. Treatment with conventional physiotherapy, electrotherapy or exercises at home was prescribed as appropriate to each one. 3 months later, the patients were examined again in consultation, using a new anamnesis, the platform and the sensors.
Study NCT05279391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe
Description: IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
Study NCT05279391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IV administration of Tocilizumab as a single dose of 8mg/kg
Study NCT05279391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: 4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
Study NCT03779438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-OHPC
Description: patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
Study NCT03779438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to 17-OHPC
Description: patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
Study NCT05279391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase Alfa Inhalant Product
Description: Inh. 2,500 U/twice daily, for up to 14 days.
Study NCT03117439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duration of antifungal therapy
Description: Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
Study NCT04625296 — intervention group
Intervention type: BEHAVIORAL
Intervention: Semi-directive interview
Description: Semi-directive interview, lasting a maximum of 45 minutes
Study NCT04625296 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire : Preparedness for Caregiving Scale
Description: Preparedness for Caregiving Scale - 8 questions
Study NCT00843778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: 200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 \[NCT00674362\], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks.
Study NCT03591770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINGRIX
Description: SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
Study NCT03591770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHINGRIX
Description: SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
Study NCT02728713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Manipulation
Description: Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
Study NCT02728713 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham/Placebo
Description: A laying on of hands with no actual treatment being performed.
Study NCT02165839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBT-I)
Study NCT02165839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating Education Learning (HEAL)
Study NCT01055652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10mg, oral, once daily
Study NCT02346773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ω-3 LC-PUFA
Description: The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.